ReNeuron has reported further improvements in the vision of patients treated with its cell therapy. The mean increase in visual acuity across the three retinitis pigmentosa (RP) patients now stands at 23 letters, well above the level deemed clinically meaningful by the FDA.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,